StockNews.AI
MRVI
StockNews.AI
173 days

Maravai LifeSciences Holdings, Inc. (MRVI) Shares Fall 21% After Delaying Q4 and FY 2024 Earnings Release, Admitting to Improper Revenue Recognition – Hagens Berman

1. Maravai's shares dropped 21% following Q4 earnings release delay. 2. Hagens Berman is investigating potential accounting misconduct at Maravai. 3. Company overstated Q2 2024 revenue by about $3.9 million. 4. Analysts downgraded Maravai’s rating and reduced price target to $3. 5. Investors are encouraged to report losses related to Maravai.

5m saved
Insight
Article

FAQ

Why Very Bearish?

The substantial drop in share price and ongoing investigations indicate a severe loss of investor confidence. Historical cases of accounting scandals, like Enron and WorldCom, demonstrate similar price declines following such announcements.

How important is it?

The article presents critical developments affecting Maravai's credibility and stock valuation. The ongoing investigation and potential accounting issues significantly heighten market scrutiny.

Why Short Term?

The immediate reaction to the news is likely to persist until clarity around the accounting issues is resolved. Such issues typically lead to volatility until full resolution.

Related Companies

NVTACRISQGEN
SAN FRANCISCO, Feb. 27, 2025 (GLOBE NEWSWIRE) -- On February 25, 2025, the share price of Maravai LifeSciences (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, plummeted 21% after the company announced it is delaying its Q4 and FY 2024 earnings release and said it requires additional time to complete its year-end financial close process. Hagens Berman is investigating possible accounting misconduct and urges investors who purchased Maravai LifeSciences shares and suffered substantial losses to submit your losses now. Visit: www.hbsslaw.com/investor-fraud/mrvi Contact the Firm Now: MRVI@hbsslaw.com                                             844-916-0895 Maravai LifeSciences Holdings, Inc. (MRVI) Investigation: The investigation is focused on the propriety of Maravai’s assurances that its financial statements are prepared in accordance with applicable accounting rules and that its internal controls over financial reporting are sufficient. The company’s assurances came into question on February 25, 2025, when Maravai announced that it postponed its Q4 and FY 2024 earnings release and conference call scheduled for that day. Maravai revealed that it: is assessing a goodwill impairment charge associated with a previous acquisition;overstated Q2 2024 revenue by approximately $3.9 million as a result of its recording the amount upon shipment in the final week of the quarter rather than on receipt by the customer; andis assessing the sufficiency of its internal controls over financial reporting, including internal controls over revenue recognition. This news sent the price of Maravai shares sharply lower on February 25, 2024, with one analyst (Baird) slashing its rating from outperform to neutral and its price target from $9 to $3. “We are investigating whether Maravai may have intentionally recorded unearned revenues,” said Reed Kathrein, the Hagens Berman Partner leading the firm's probe. If you invested in Maravai and have substantial losses, or have knowledge that may assist the firm’s investigation, submit your losses now » If you’d like more information and answers to frequently asked questions about the Maravai investigation, read more » Whistleblowers: Persons with non-public information regarding Maravai should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 844-916-0895 or email MRVI@hbsslaw.com. About Hagens BermanHagens Berman is a global plaintiffs’ rights complex litigation firm focusing on corporate accountability. The firm is home to a robust practice and represents investors as well as whistleblowers, workers, consumers and others in cases achieving real results for those harmed by corporate negligence and other wrongdoings. Hagens Berman’s team has secured more than $2.9 billion in this area of law. More about the firm and its successes can be found at hbsslaw.com. Follow the firm for updates and news at @ClassActionLaw. Contact: Reed Kathrein, 844-916-0895

Related News